A 2-week open, randomized, crossover study was conducted in epileptic patients on chronic therapy, who took either carbamazepine (CBZ) 200 or CBZ 400 mg tablets. The oral dose was 1200 or 1600 mg/day, according to individual needs. There was no difference in absorption or steady-state levels between the two preparations. The new galenic preparation of CBZ will help the neurologist to reduce the number of tablets taken by severe epileptic patients, with no risk but only benefits for the subjects.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/030006058401200208 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Effect of Gallic Acid on the Alleviation of the Chemotherapy-Induced Myelosuppression.
Curr Med Chem
January 2025
Department of Urology, Children's Hospital of Chongqing Medical University, Chongqing, 400014, P.R. China.
Objective: This study aims to investigate the effect of Gallic Acid (GA) on the alleviation of chemotherapy-induced bone marrow suppression, with a comparison to Diyu sheng bai tablets (DYSB) and RhG-CSF.
Methods: A mouse model of bone marrow suppression was established in BALB/c mice using intraperitoneal injections of cyclophosphamide (CTX). All procedures were performed after obtaining ethical clearance from the institutional animal ethics committee.
Albendazole-ivermectin co-formulation for the treatment of Trichuris trichiura and other soil-transmitted helminths: a randomised phase 2/3 trial.
Lancet Infect Dis
January 2025
Barcelona Institute for Global Health, Barcelona, Spain; International Health Department, Hospital Clinic de Barcelona, Barcelona, Spain; Universitat de Barcelona, Barcelona, Spain. Electronic address:
Background: Treatments for soil-transmitted helminthiases face challenges, especially in addressing Trichuris trichiura. Combination regimens, particularly of ivermectin and albendazole, are promising. We aimed to assess the safety, efficacy, and palatability of a combination tablet for the treatment of T trichiura, hookworm, and Strongyloides stercoralis infections among school-aged children in Ethiopia, Kenya, and Mozambique.
View Article and Find Full Text PDFComparative pharmacokinetics study of two tablet formulations of delpazolid, a novel oxazolidinone class antibiotic.
Transl Clin Pharmacol
December 2024
Department of Clinical Pharmacology and Therapeutics, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Korea.
Unlabelled: Delpazolid is an oxazolidinone-class antibiotic under development for treating diseases caused by antimicrobial-resistant gram-positive bacteria. This study compared the pharmacokinetics (PK) and safety of two formulations of delpazolid 400 mg with distinct excipient compositions: Batch No. 3183817R (test drug) and Batch No.
View Article and Find Full Text PDFEfficacy of Natural β-Carotene Chewable Tablets Derived from Banana ( AA) Pulp in Reducing UV-Induced Skin Erythema.
Nutrients
December 2024
Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences and Center of Excellence for Innovation in Chemistry, Naresuan University, Phitsanulok 65000, Thailand.
Background/objectives: UV radiation is a primary cause of skin damage and photoaging. β-carotene, a potent antioxidant, aids in mitigating UV-induced oxidative stress and enhancing skin photoprotection. This research aimed to evaluate the efficacy of a nutraceutical product designed to prevent photoaging.
View Article and Find Full Text PDFImportance: Among older adults with ischemic heart disease, participation in traditional ambulatory cardiac rehabilitation (CR) remains low. While mobile health CR (mHealth-CR) provides a novel opportunity to deliver care, age-specific impairments to technology use may limit uptake, and efficacy data are currently lacking.
Objective: To test whether mHealth-CR improves functional capacity in older adults.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!